as anti-Müllerian hormone (AMH) 7 and testosterone which are made by the gonads. 8 Few studies have examined these ovarian markers among women with type 1 diabetes after their adolescence and early twenties. For several reasons, it is important to examine ovarian markers and predictors of such markers at older ages. In general, women are at increased risk of infertility as they age, particularly in their thirties or their 4th decade of life. 9 Due to years of intensive insulin therapy, women with type 1 diabetes may be particularly vulnerable to obesity as they age. 10 Longer duration of diabetes and prolonged exposure to elevations in glucose could also adversely affect the ovary through deposition of advanced glycation end-products. 11 Exogenous insulin may also have gonadotropic effects, 12 particularly because supraphysiologic systemic insulin levels are significantly higher in persons with type 1 diabetes due to the need to achieve physiologic levels in the portal circulation. 13 Therefore, due to previous reports noting increased risk for infertility among women with type 1 diabetes as well as prior reports noting high prevalence of PCOS among women with type 1 diabetes, 13 we examined the prevalence of elevations in AMH and testosterone and associations with irregular menses and diabetes-specific variables.
We conducted a secondary analysis of a large population of wellcharacterized reproductive-age women (n = 379 women) with type 1 diabetes with an average of 35 years. We used data from participants
in Epidemiology of Diabetes Interventions and Complications (EDIC)
study, 14 which is the ongoing observational follow-up to the Diabetes
Control and Complications Trial (DCCT)
. 15 We hypothesized that irregular menses as well as longer diabetes duration, higher body mass index (BMI), poorer glycemic control and higher insulin dosage would be associated with abnormal concentrations in ovarian markers.
| MATERIALS AND METHODS

| Population and Setting
The DCCT and EDIC studies have been described in detail. Briefly, the DCCT was a multicenter, randomized clinical trial designed to compare the impact of intensive vs conventional diabetes treatment on the development and progression of early microvascular complications of type 1 diabetes. 16 From 1983 to 1989, 1441 patients (including 680 women) were enrolled at 29 centres. The goal of intensive therapy was to maintain glycemic control as close to the nondiabetic range as possible using ≥3 daily insulin injections or an insulin pump, with dose adjustment guided by frequent selfmonitoring of blood glucose. Conventional treatment consisted of 1-2 daily insulin injections without stipulated target glucose concentrations. The DCCT included a primary prevention cohort and a secondary intervention cohort. The primary prevention cohort consisted of 726 subjects with no retinopathy, urinary albumin excretion rate <40 mg/24 h and diabetes duration of 1-5 years at DCCT baseline. The secondary intervention cohort consisted of 715 subjects who had nonproliferative retinopathy, urinary albumin excretion rate ≤200 mg/24 h and diabetes duration of 1-15 years.
Individuals were excluded from participating in the DCCT if they were hypertensive, taking any blood pressure or lipid-lowering medications, or had a history of symptomatic ischaemic heart disease or symptomatic peripheral neuropathy. Informed consent was obtained from all participants through the institutional review boards at participating centres.
Beginning in 1994 and continuing to the present, clinical, behavioural and biochemical end-points have been obtained annually during EDIC by history, physical examination and laboratory testing.
Variables include smoking, BMI, waist circumference, insulin dosage, medication use and haemoglobin A1c (HbA1c). The EDIC standardized annual history included a detailed interview regarding menstrual patterns or discontinuation of menses, gynaecologic surgeries, and use of exogenous hormones, particularly oral contraceptive pill (OCP) use. 17 At each of these annual interviews, women were asked "Since the last visit, has the patient had any changes to the conditions mentioned below?" "Irregular menses" was specifically listed as a condition, and women were classified as having any history of irregular menses (yes/no).
Under a separate ancillary study mechanism, a sample of 415 women who had not undergone gynaecologic surgery was selected for measurement of AMH. Strategies for sample selection have been previously For values less than the limit of quantification but above the lower limit of detection, SoftMax Pro software (Sunnyvale, CA) was used
to plot values, fit a cubic regression curve and create splines which were then used to calculate AMH concentrations.
Total serum testosterone was quantitated at the EDIC CBL using a rapid liquid chromatography-tandem mass spectrophotometry assay 
| Statistical analysis
We examined the proportion of women with elevated AMH, elevated testosterone concentrations and histories of irregular menses, as well as combinations of these reproductive abnormalities. We examined the unadjusted associations between the initial AMH/testosterone concentrations in EDIC years 1-4 and other variables measured concurrently (Table 2 ). Multivariable models were used to examine the adjusted associations between risk factors and AMH or testosterone (Tables S1 and S2 ). AMH and testosterone concentrations were log-transformed for analysis. The per cent change in AMH or testosterone concentration per unit increase in concurrent risk factor or the per cent difference in the mean AMH concentration is presented. HbA1c levels and total daily insulin dose were evaluated as time-weighted variables defined as the running arithmetic mean up to the point of the dependent variable measurement. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA). 
| RESULTS
| DISCUSSION
As women age, they are more likely to report difficulties with fertility, with fecundity decreasing gradually after 32 years of age and Women using OCPs at the time of AMH and testosterone measurement were excluded, although 5 women were using OCPs at baseline but not at subsequent visits when testosterone was measured.
more rapidly after 37 years of age. 9 Few reports have examined abnormalities in ovarian markers in women with type 1 diabetes in this age range, although as many as a third of younger women with type 1 diabetes may have PCOM and androgen abnormalities. 13 In a relatively large cohort of well-phenotyped women with type 1 diabetes with a median age of 35 years, we found that AMH elevations T A B L E 2 Mean ± SD initial anti-Müllerian hormone (AMH) and testosterone concentrations in EDIC years 1-4 by concurrent risk factors. Therefore, elevations in AMH are common and could potentially explain decreased fecundity in women with type 1 diabetes, apart from irregular menses.
We also found that factors associated with higher AMH included younger age, higher testosterone concentrations and not currently smoking as has been reported in other studies. 21 In contrast to other reports, we note that lower insulin doses over time were also correlated with higher AMH concentrations, suggesting that in this late
reproductive-age population, higher exogenous insulin does not act as a gonadotropin and thus does not result in elevations in ovarian markers. Previous reports conflict. 20, 22 We may have found different results due to the relatively older age of our population and our use of timeweighted variables, which accounts for longitudinal changes in insulin dosing over time, as opposed to previous cross-sectional analyses. We also included a significantly larger number of women than in previous reports, which included less than women with type 1 diabetes.
20,22
The factors associated with higher testosterone concentration included higher AMH and a history of smoking, which was likely due to the fact that women using OCPs were excluded; thus, women who had testosterone measurement were younger and already more likely to smoke than women who did not have testosterone measurement.
Due to the presence of insulin receptors on the ovary and associations between elevations in testosterone with PCOM, others have hypothesized that exogenous insulin may act as a gonadotropin in type 1 diabetes. In EDIC women, insulin did not appear to be associated with elevated testosterone concentrations. 23 This may be because the presence of significant elevations in testosterone was rare in EDIC women.
In addition, previous reports note that among women with known hyperandrogenemia, androgen levels decline as women age particularly beginning in the 4th decade of life, 24, 25 which may also account for the lower androgen levels.
Neither AMH nor testosterone elevations were correlated with the prevalence of irregular menses, even though histories of irregular menses were common in the EDIC population and among other cohorts of women with type 1 diabetes. 26, 27 Thus, irregular menses may independently contribute to decreased risk of fecundity apart from these pathways. Multiple endocrinologic disorders can result in irregular menses, including disorders that are more common in women with type 1 diabetes than in women without diabetes; we have previously reported that the risk of hypothyroidism was high in EDIC, with approximately 25% of women noting hypothyroidism by the 18th year of EDIC follow-up. 6 Others have noted that women with type 1 diabetes have abnormal gonadotropin-releasing hormone pulse generation which may also result in irregular menstrual cycles.
28
Strengths of this report include its large and well-characterized population of women with type 1 diabetes who were of older age than in previous reports examining ovarian markers. We used an AMH assay with higher sensitivity and precision than presented in previous studies that used first-generation assays, which may be less subject to issues of performance and interpretation than transvaginal ultrasound. 7 Testosterone was performed with mass spectrometry, generally considered more sensitive than other methods, 29 an issue particularly important in women. This report also has several limitations. The assessment of reproductive abnormalities was not a primary objective of the EDIC study, and thus, women were not asked to record cycle length with menstrual diaries. EDIC did not conduct transvaginal ultrasounds to assess ovarian morphology nor clinical assessments of hyperandrogenism such as measurement of Ferriman-Gallwey scores. Difficulties with fertility and actual thyroid hormone levels were not assessed. There are no universal cutpoints for abnormal levels of AMH and testosterone. 19 We examined cutpoints corresponding with the 25th percentile of total testosterone as well as with the 50th percentile compared to previous reports in younger populations, and thus, it is unlikely that lower cutpoints would lead to a significantly higher prevalence of hyperandrogenism. 20 Testosterone was assessed only in women not using OCPs, and it is possible that clinical hyperandrogenemia was masked among the 14% of women who were OCP users or that testosterone concentrations were less elevated among women who chose not to use OCPs, thus underestimating the proportion of women with hyperandrogenemia.
Finally, it is unknown whether the relationships between AMH, testosterone, irregular menses and PCOS differ between women with and without type 1 diabetes. We did not conduct a comparison between women with and without diabetes. In a previous report, we noted that women in EDIC had lower AMH concentrations than women in a control group and that these lower concentrations were primarily attributable to a slightly lower prevalence of elevated AMH and Escobar-Morreale et al also noted that testosterone concentrations were higher among women with type 1 diabetes without PCOS (n = 52) compared to controls (n = 18). 33 We conclude that the prevalence of abnormalities in ovarian markers, specifically elevations in AMH, is common in women with type 1 diabetes at an age where they are at increased risk for infertility. 
